KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to 5.11%.

  • Jazz Pharmaceuticals' EBIT Margin fell 195600.0% to 5.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.46%, marking a year-over-year decrease of 217000.0%. This contributed to the annual value of 17.61% for FY2024, which is 25200.0% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported EBIT Margin of 5.11% as of Q3 2025, which was down 195600.0% from 65.64% recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year EBIT Margin high stood at 26.68% for Q1 2021, and its period low was 65.64% during Q2 2025.
  • In the last 5 years, Jazz Pharmaceuticals' EBIT Margin had a median value of 9.96% in 2022 and averaged 5.04%.
  • In the last 5 years, Jazz Pharmaceuticals' EBIT Margin skyrocketed by 621500bps in 2021 and then tumbled by -851200bps in 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' EBIT Margin (Quarter) stood at 5.51% in 2021, then crashed by -592bps to 27.09% in 2022, then skyrocketed by 145bps to 12.11% in 2023, then skyrocketed by 45bps to 17.53% in 2024, then crashed by -71bps to 5.11% in 2025.
  • Its EBIT Margin was 5.11% in Q3 2025, compared to 65.64% in Q2 2025 and 17.53% in Q4 2024.